Literature DB >> 14500898

IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Stephane Wong1, Jami McLaughlin, Donghui Cheng, Kevin Shannon, Lorraine Robb, Owen N Witte.   

Abstract

BCR-ABL expression led to a dramatic up-regulation of the IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor receptor beta common (IL-3Rbetac) and IL-3 receptor beta (IL-3Rbeta) chains in murine embryonic stem cell-derived hematopoietic cells coincident with an expansion of multipotent progenitors and myeloid elements. This up-regulation required BCR-ABL tyrosine kinase activity and led to IL-3Rbetac/beta chain tyrosine phosphorylation in the absence of detectable IL-3 production. These results suggested that cytokine-independent IL-3 receptor activation could be a dominant signaling component in BCR-ABL-induced leukemogenesis. To unambiguously define the significance of IL-3 receptor-dependent signaling in BCR-ABL-induced leukemogenesis, BCR-ABL-transduced bone marrow cells deficient in either IL-3Rbetac chain or both IL-3Rbetac/beta chain expression were examined for their ability in generating myeloproliferative disease (MPD). These BCR-ABL-expressing knockout cells were capable of generating MPD similar to control cells, demonstrating that IL-3 receptor activation is not essential for BCR-ABL-induced MPD. However, the IL-3Rbetac/beta chain could act as a cofactor in BCR-ABL-induced leukemogenesis by activation of its many known oncogenic signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500898      PMCID: PMC208809          DOI: 10.1073/pnas.2035020100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

Authors:  X Jiang; A Lopez; T Holyoake; A Eaves; C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Increased expression of the distal, but not of the proximal, Gata1 transcripts during differentiation of primary erythroid cells.

Authors:  A M Vannucchi; S Linari; C S Lin; M J Koury; M C Bondurant; A R Migliaccio
Journal:  J Cell Physiol       Date:  1999-09       Impact factor: 6.384

3.  Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression.

Authors:  Hisamitsu Ide; David B Seligson; Sanaz Memarzadeh; Li Xin; Steve Horvath; Purnima Dubey; Maryann B Flick; Barry M Kacinski; Aarno Palotie; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

4.  Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.

Authors:  T Era; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

5.  Nf1 and Gmcsf interact in myeloid leukemogenesis.

Authors:  R A Birnbaum; A O'Marcaigh; Z Wardak; Y Y Zhang; G Dranoff; T Jacks; D W Clapp; K M Shannon
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

6.  Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors.

Authors:  Q Sun; K Jones; B McClure; B Cambareri; B Zacharakis; P O Iversen; F Stomski; J M Woodcock; C J Bagley; R D'Andrea; A F Lopez
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

7.  Functional and molecular analysis of hematopoietic progenitors derived from the aorta-gonad-mesonephros region of the mouse embryo.

Authors:  S Delassus; I Titley; T Enver
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

8.  Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor.

Authors:  C L Scott; L Robb; B Papaevangeliou; R Mansfield; N A Nicola; C G Begley
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

9.  Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common beta subunit.

Authors:  M P McCormack; T J Gonda
Journal:  Oncogene       Date:  1999-12-02       Impact factor: 9.867

10.  SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.

Authors:  A M Pendergast; M L Gishizky; M H Havlik; O N Witte
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

View more
  5 in total

Review 1.  Following the cytokine signaling pathway to leukemogenesis: a chronology.

Authors:  Kendall A Smith; James D Griffin
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

2.  Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.

Authors:  S Wong; J McLaughlin; D Cheng; C Zhang; K M Shokat; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

Review 3.  Emerging role of human basophil biology in health and disease.

Authors:  Jessica L Cromheecke; Kathleen T Nguyen; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2014-01       Impact factor: 4.806

4.  DNA sequence and analysis of human chromosome 9.

Authors:  S J Humphray; K Oliver; A R Hunt; R W Plumb; J E Loveland; K L Howe; T D Andrews; S Searle; S E Hunt; C E Scott; M C Jones; R Ainscough; J P Almeida; K D Ambrose; R I S Ashwell; A K Babbage; S Babbage; C L Bagguley; J Bailey; R Banerjee; D J Barker; K F Barlow; K Bates; H Beasley; O Beasley; C P Bird; S Bray-Allen; A J Brown; J Y Brown; D Burford; W Burrill; J Burton; C Carder; N P Carter; J C Chapman; Y Chen; G Clarke; S Y Clark; C M Clee; S Clegg; R E Collier; N Corby; M Crosier; A T Cummings; J Davies; P Dhami; M Dunn; I Dutta; L W Dyer; M E Earthrowl; L Faulkner; C J Fleming; A Frankish; J A Frankland; L French; D G Fricker; P Garner; J Garnett; J Ghori; J G R Gilbert; C Glison; D V Grafham; S Gribble; C Griffiths; S Griffiths-Jones; R Grocock; J Guy; R E Hall; S Hammond; J L Harley; E S I Harrison; E A Hart; P D Heath; C D Henderson; B L Hopkins; P J Howard; P J Howden; E Huckle; C Johnson; D Johnson; A A Joy; M Kay; S Keenan; J K Kershaw; A M Kimberley; A King; A Knights; G K Laird; C Langford; S Lawlor; D A Leongamornlert; M Leversha; C Lloyd; D M Lloyd; J Lovell; S Martin; M Mashreghi-Mohammadi; L Matthews; S McLaren; K E McLay; A McMurray; S Milne; T Nickerson; J Nisbett; G Nordsiek; A V Pearce; A I Peck; K M Porter; R Pandian; S Pelan; B Phillimore; S Povey; Y Ramsey; V Rand; M Scharfe; H K Sehra; R Shownkeen; S K Sims; C D Skuce; M Smith; C A Steward; D Swarbreck; N Sycamore; J Tester; A Thorpe; A Tracey; A Tromans; D W Thomas; M Wall; J M Wallis; A P West; S L Whitehead; D L Willey; S A Williams; L Wilming; P W Wray; L Young; J L Ashurst; A Coulson; H Blöcker; R Durbin; J E Sulston; T Hubbard; M J Jackson; D R Bentley; S Beck; J Rogers; I Dunham
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

5.  ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1.

Authors:  M Thai; P Y Ting; J McLaughlin; D Cheng; M Müschen; O N Witte; J Colicelli
Journal:  Leukemia       Date:  2010-11-19       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.